CYGS Patent Claims Allowed for ssDNA Vector and NCI/NIH Researcher Joins Scientific Advisory Board.HOUSTON--(BUSINESS WIRE)--Jan 10, 1999--Cryogenic Solutions, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:CYGS) announced today that its principal research facility, InGene, Inc., has received notice of allowance from the U.S. Patent and Trademark Office for a patent application entitled Stem-Loop Cloning Vector cloning vector n. An autonomously replicating plasmid having regions into which foreign DNA can be inserted. And Method. CYGS is the exclusive licensee of this application from InGene. It is anticipated that the patent will issue in the summer of 1999. This patent application relates to the production and use of single stranded DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. expression vectors expression vector n. A vector, such as a plasmid, yeast, or animal virus genome, used to introduce foreign genetic material into a host cell in order to replicate and amplify the foreign DNA sequences as a recombinant molecule. which, among other things, can be used in synthesizing sequence specific, antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). competent oligodeoxyribonucleotides in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. . Effective delivery of antisense molecules offers a promising method for treatment of a number of diseases and disorders at the most basic genetic level, eliminating the need for drugs or surgery to treat symptoms or repair the damage caused by faulty, impaired, or inactive genes. CYGS is currently conducting experiments to demonstrate that their ssDNA expression vector delivers antisense molecules into the cells of living animals, including humans, in sufficient quantities to be pharmacologically significant. CYGS also announced the addition to the company*s Scientific Advisory Board of Stephen M. Hewitt, M.D., Ph.D. Dr. Hewitt was awarded a Ph.D. in Genetics from The University of Texas Health Science Center and the M. D. Anderson Cancer Center in 1995 before earning his M.D. at the University of Texas Health Science Center, Houston Medical School in 1996. He is currently conducting medical research as a resident in Anatomic Pathology in the Laboratory of Pathology, National Cancer Institute, National Institute of Health. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion